Update to living WHO guideline on drugs for covid-19

The latest version of this WHO living guidance focuses on remdesivir, following the preprint publication of results from the WHO SOLIDARITY trial. It contains a weak or conditional recommendation against the use of remdesivir in hospitalised patients with covid-19.

British Medical Journal